Grifols, S.A. (GRFS) Rating Lowered to Hold at Zacks Investment Research

Grifols, S.A. (NASDAQ:GRFS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

Several other equities research analysts have also recently weighed in on GRFS. BidaskClub cut shares of Grifols, from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Goldman Sachs Group, Inc. (The) cut shares of Grifols, from a “buy” rating to a “neutral” rating in a research report on Friday, June 30th. Finally, Bank of America Corporation reiterated a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Grifols, has a consensus rating of “Hold” and a consensus price target of $24.00.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://sportsperspectives.com/2017/10/13/grifols-s-a-grfs-rating-lowered-to-hold-at-zacks-investment-research.html.

Large investors have recently modified their holdings of the company. Advisory Services Network LLC grew its position in shares of Grifols, by 26.2% during the 2nd quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after buying an additional 1,987 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Grifols, during the 2nd quarter worth approximately $223,000. Stifel Financial Corp grew its position in shares of Grifols, by 4.3% during the 1st quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after buying an additional 476 shares during the period. Stevens Capital Management LP acquired a new stake in shares of Grifols, during the 2nd quarter worth approximately $236,000. Finally, Advisor Group Inc. grew its position in shares of Grifols, by 2.8% during the 2nd quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after buying an additional 309 shares during the period. Institutional investors own 21.93% of the company’s stock.

About Grifols,

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply